Artificial Intelligence (AI) In Biopharmaceuticals Market Report 2026

Artificial Intelligence (AI) In Biopharmaceuticals Market Overview

• Artificial Intelligence (AI) In Biopharmaceuticals market size has reached to $2.1 billion in 2025 • Expected to grow to $8.77 billion in 2030 at a compound annual growth rate (CAGR) of 33.1% • Growth Driver: Chronic Disease Prevalence Fueling Growth Of AI In Biopharmaceuticals Market • Market Trend: Advancements In AI-Powered Solutions For Drug Discovery And Precision Medicine • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Artificial Intelligence (AI) In Biopharmaceuticals Market?

Artificial intelligence (AI) in biopharmaceuticals refers to applying various AI techniques to analyze complex biological data and improve various aspects of drug discovery, development, and delivery within the pharmaceutical industry. AI in biopharmaceuticals holds great promise for revolutionizing drug discovery, development, and delivery processes by accelerating timelines, reducing costs, and improving the efficiency and effectiveness of treatments. The main types of offerings in artificial intelligence (AI) in biopharmaceuticals are hardware, software, and services. Hardware refers to the physical components of a computer system, including devices such as memory, disk drives, controllers, and specialized software like database management systems. It includes various deployments, including cloud and on-premises, and the technologies used are machine learning, natural language processing, and deep learning, as well as applications used in business processes and supply chains, drug discovery, medical imaging and diagnostics, and precision medicine, end users are manufacturers, contract research organizations, and academic and government research institutes.

What Is The Artificial Intelligence (AI) In Biopharmaceuticals Market Growth Forecast?

The artificial intelligence (ai) in biopharmaceuticals market size is expected to see exponential growth in the next few years. It will grow to $8.77 billion in 2030 at a compound annual growth rate (CAGR) of 33.1%. The growth in the forecast period can be attributed to advancements in machine learning algorithms, expansion of ai-enabled lab equipment, increased adoption of predictive analytics, rise in collaborative ai-biopharma platforms, government incentives for ai-driven healthcare. Major trends in the forecast period include ai-driven drug discovery, predictive analytics for clinical trials, automation in laboratory processes, real-world data integration, personalized treatment optimization.

Global Artificial Intelligence (AI) In Biopharmaceuticals Market Segmentation

1) By Offering: Hardware, Software, Services 2) By Deployment: Cloud, On-Premises 3) By Technology: Machine Learning, Natural Language Processing, Deep Learning, Other Technologies 4) By Application: Drug Discovery, Precision Medicine 5) By End-Users: Manufacturers, Contract Research Organizations, Academic And Government Research Institutes Subsegments: 1) By Hardware: High-Performance Computing Systems, AI-Enabled Laboratory Equipment, Data Storage Solutions 2) By Software: Drug Discovery Platforms, Predictive Analytics Tools, Natural Language Processing Solutions 3) By Services: Consulting Services, Implementation And Integration Services, Data Management And Analytics Services, Training And Support Services

What Is The Driver Of The Artificial Intelligence (AI) In Biopharmaceuticals Market?

The growing prevalence of chronic diseases is expected to propel the growth of artificial intelligence (AI) in biopharmaceuticals market going forward. Chronic diseases are long-lasting conditions that generally progress slowly and may persist for years or even a lifetime. It arises from lifestyle factors, an aging population, genetic predispositions, and environmental factors. AI in biopharmaceuticals is increasingly used to manage chronic diseases because it analyzes large volumes of diverse data sources, identifies patterns, and personalizes treatment approaches. For instance, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency. in 2023, approximately 194 million U.S. adults, or 76.4%, reported having at least one chronic condition. The prevalence was 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, the growing prevalence of chronic diseases drives the growth of artificial intelligence (AI) in the biopharmaceuticals market.

Key Players In The Global Artificial Intelligence (AI) In Biopharmaceuticals Market

Major companies operating in the artificial intelligence (ai) in biopharmaceuticals market are Exscientia Limited, DeepMind Technologies Limited, Schrödinger Inc., XtalPi Inc., ConcertAI Inc., Insilico Medicine Inc., Recursion Pharmaceuticals, BenevolentAI, BioXcel Therapeutics, Atomwise Inc., BioAge Labs Inc., GNS Healthcare, Berg Health, Deep 6 AI Inc., Cloud Pharmaceuticals Inc., Numerate Inc., AI Therapeutics, Envisagenics, twoXAR Inc., Cyclica Inc.

Global Artificial Intelligence (AI) In Biopharmaceuticals Market Trends and Insights

Major companies operating in artificial intelligence (AI) in biopharmaceuticals focus on developing innovative advancements such as target and lead identification suite AI-powered solutions to accelerate drug discovery and precision medicine to transform life sciences organizations. These solutions for drug discovery and precision medicine encompass a variety of innovative approaches to developing new drugs and tailoring treatments to individual patients. For instance, in May 2023, Google LLC, a US-based provider of cloud computing services, launched two new AI-powered tools called target and lead identification suites, designed to help researchers predict and understand the structure of proteins, which is a fundamental part of drug development. Additionally, this suite will help researchers ingest, store, analyze, and share mass amounts of genomic data, which is crucial for precision medicine. Also, these tools aim to streamline the drug discovery process, reduce costs, and bring new treatments to market faster. By providing efficient data management, accurate predictions of protein structures, and advanced genomic analysis capabilities, these tools aim to revolutionize drug development processes and improve patient outcomes.

What Are Latest Mergers And Acquisitions In The Artificial Intelligence (AI) In Biopharmaceuticals Market?

In February 2023, ZS Associates, a US-based management consulting and technology firm, acquired Trials.ai Inc. for an undisclosed amount. With this acquisition, Associates aims to enhance design processes within the pharmaceutical industry by leveraging artificial intelligence (AI) to optimize speed, improve participant experiences, and expedite the delivery of pharmaceutical therapies to the market. Trials.ai Inc. is a US-based company that focuses on revolutionizing clinical trials through artificial intelligence (AI) and machine learning (ML) technologies.

Regional Insights

North America was the largest region in the artificial intelligence (AI) in biopharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Artificial Intelligence (AI) In Biopharmaceuticals Market?

The artificial intelligence (AI) in biopharmaceuticals market consists of revenues earned by entities by services such as drug discovery, personalized medicine analytics, clinical trial optimization, healthcare decision support, and data integration and analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) in biopharmaceuticals market also includes of sales of decision support System, predictive modeling tools, robotics, and automation systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Artificial Intelligence (AI) In Biopharmaceuticals Market Report 2026?

The artificial intelligence (ai) in biopharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (ai) in biopharmaceuticals industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.